tiprankstipranks
Tonix Pharma (TNXP)
NASDAQ:TNXP

Tonix Pharma (TNXP) Income Statement

2,222 Followers

Tonix Pharma Income Statement

Last quarter (Q3 2023), Tonix Pharma's total revenue was $3.99M, an increase of Infinity% from the same quarter last year. In Q3, Tonix Pharma's net income was $-27.98M. See Tonix Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 3.99M--$ 0.00$ 0.00$ 0.00
Cost of Revenue
$ 2.37M-----
Gross Profit
$ 1.61M-----
Operating Expense
$ 57.59M$ 112.09M$ 92.31M$ 50.51M$ 28.83M$ 26.32M
Operating Income
$ -55.98M$ -112.09M$ -92.31M$ -50.51M$ -28.83M$ -26.32M
Net Non Operating Interest Income Expense
$ 2.76M$ 1.87M$ 25.00K$ 48.00K$ 210.00K$ 233.00K
Other Income Expense
------
Pretax Income
$ -50.84M$ -110.22M$ -92.29M$ -50.46M$ -28.62M$ -26.09M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -55.62M$ -116.88M$ -92.29M$ -52.17M$ -31.09M$ -29.36M
Basic EPS
$ -6.34$ -3.27$ -1.63$ -17.60$ -19.33$ -259.85
Diluted EPS
$ -6.34$ -3.27$ -1.63$ -17.60$ -19.33$ -259.85
Basic Average Shares
$ 125.01M$ 35.74M$ 57.63M$ 2.96M$ 1.61M$ 112.97K
Diluted Average Shares
$ 125.01M$ 35.74M$ 57.63M$ 2.96M$ 1.61M$ 112.97K
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 59.96M$ 112.09M$ 92.31M$ 50.51M$ 28.83M$ 26.32M
Interest Expense
------
Net Income From Continuing And Discontinued Operation
$ -121.02M$ -110.22M$ -92.29M$ -50.46M$ -28.62M$ -26.09M
Normalized Income
$ -42.63M--$ -50.46M$ -28.62M$ -26.09M
EBIT
$ -51.89M$ -110.22M$ -92.29M$ -50.51M$ -28.83M$ -26.32M
EBITDA
$ -49.94M$ -108.97M$ -92.24M$ -50.48M$ -28.80M$ -26.27M
Currency in USD

Tonix Pharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis